Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines, primarily through its lead candidate Plogo, a PLK1 inhibitor.

# Company Overview: Cyclacel Pharmaceuticals, Inc.

## Business Focus:
- Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative cancer medicines.  
- The company's core expertise lies in cell cycle biology, epigenetics, and mitosis biology with the aim of creating therapies that can overcome resistance and increase overall survival rates in cancer patients.

## Key Drug Program:
- **Lead Candidate:** Plogo (formerly CYC140), a PLK1 (polo-like kinase 1) inhibitor.
- **Development Stage:** Currently in Phase 1/2 clinical trials targeting solid tumors (such as colorectal, breast, esophageal, gastric, ovarian, lung cancers, and lymphomas) and hematological malignancies.
- **Mechanism:** Plogo is a highly selective, small molecule oral inhibitor targeting PLK1, a key regulator of cell division involved in cancer cell proliferation and DNA damage response.
- **Clinical Trial Design:** The trial aims to establish the recommended Phase 2 dose, evaluate safety, and gather signals of efficacy across multiple cancer types, including GI cancers, lung, ovarian, and biomarker-defined tumor baskets.
- **Formulation:** Developing an oral formulation of Plogo with improved bioavailability.

## Business Strategy:
- Focus on the continued development of Plogo following strategic reviews and asset liquidation.
- Retain rights to market and develop Plogo; plan to seek partnerships for further development and commercialization.
- External collaborations and licensing are part of the strategy, although the current focus is solely on Plogo.
- The company has retained worldwide rights to Plogo and is exploring strategic alternatives to preserve capital and optimize value.

## Company Size and Financials:
- **Number of Shares Outstanding (as of March 27, 2025):** 207,336,389 shares of common stock.
- **Market Capitalization (as of June 30, 2024):** Approximately $2.52 million (based on a stock price of $1.62 per share).
- **Employees:** Not explicitly stated.
- **Revenue:** No specific revenue figures provided.
- **Income:** The company has a history of operating losses; as of December 31, 2024, the accumulated deficit is approximately $439.5 million and net loss for 2024 was $11.2 million.

## Recent Developments:
- Conducting a liquidation of its wholly owned UK subsidiary, Cyclacel Limited.
- Entered into a securities purchase agreement with investor David Lazar, raising $3.1 million.
- Focused solely on the development of Plogo, with other programs such as fadraciclib being marketed for sale or liquidated.

## Scientific and Technical Focus:
- Emphasizes targeted cancer therapy focusing on cell cycle regulation.
- Discovered and developed potent inhibitors of PLK1, a kinase involved in cell division, with data showing high activity against various tumor xenografts.
- Aims for oral, convenient dosing schedules and improved pharmaceutical properties over earlier compounds.

This summary encapsulates Cyclacel's core activities, pipeline, strategic focus, and financial status based solely on provided information.

Cyclacel Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative cancer treatments by leveraging proprietary cell cycle control technology.

# Cyclacel Pharmaceuticals, Inc. Overview

**Company Profile:**
Cyclacel Pharmaceuticals, Inc. is a biotechnology company focused on the development of innovative medicines for the treatment of cancer and other diseases. Based in Berkeley Heights, New Jersey, the company leverages its proprietary cell cycle control technology to create therapeutic candidates.

## Core Business and Technology
- **Primary Focus**: Cyclacel is dedicated to developing drug candidates that target critical mechanisms of cell cycle regulation. Its approach centers on manipulating the cell cycle for therapeutic benefit, particularly in the areas of oncology.
- **Technology Platform**: The company utilizes research and development in areas such as:
  - Cancer therapeutics
  - Targeting the cell cycle and apoptosis (programmed cell death)
  - Investigational medicines for rare and hematologic cancers

## Products and Pipeline
Cyclacel's product candidates include:
1. **CYC065**: An oral CDK2/9 inhibitor currently in clinical trials for treating cancer.
2. **CYC140**: A selective Aurora kinase A inhibitor.
3. **CYC088**: A potent small molecule that targets multiple cell cycle checkpoints.

### Clinical Trials
Cyclacel is involved in numerous clinical trials aimed at evaluating the efficacy and safety of its drug candidates. The results from these trials influence the progress toward regulatory approvals and potential commercialization.

## Employees
As of the latest filing, Cyclacel employs approximately **51 to 200 employees**, consisting of research scientists, regulatory affairs experts, clinical operations staff, and business professionals focused on finance and operations.

## Financial Overview
- **Revenue**: The company’s revenue largely comes from research grants, collaborations, and equity financing rather than product sales. In past reports, revenue figures have fluctuated but indicate significant reliance on partnerships and grants to fund operations.
- **Income**: The detailed financial results reflect significant investments in research and development, leading to net losses as is typical for companies in the clinical development stage. For the year ending December 31, 2023, Cyclacel reported financial results showcasing operational losses due to ongoing clinical trials and development costs, consistent with its business model.

## Customer Base
Unlike traditional businesses with a direct customer base, Cyclacel interacts primarily with:
- **Collaborators and Partners**: Collaborations with larger pharmaceutical companies and research institutions.
- **Regulatory Bodies**: Engaging with the FDA and other regulatory agencies during drug development and approval processes.

## Conclusion
Cyclacel Pharmaceuticals, Inc. stands out as a biotechnology company with a robust pipeline and innovative approach to cancer treatment, emphasizing cell cycle regulation. It operates with a focused strategy on R&D, supported by clinical trials that seek to bring valuable therapies to market for the oncology landscape. The financial focus remains on grants and collaborations, reflective of the early-stage nature of its product development.

Cyclacel Pharmaceuticals, Inc.

10-K / April 2, 2025

10-K / April 29, 2024

10-K / April 2, 2025

Company Overview: Cyclacel Pharmaceuticals, Inc.

Business Focus:

Key Drug Program:

Business Strategy:

Company Size and Financials:

Recent Developments:

Scientific and Technical Focus: